Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy

  • Núria AlonsoEmail author
  • Pedro Moliner
  • Dídac Mauricio
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1067)


Patients with type 1 and type 2 diabetes mellitus (T1D and T2D) show an increased incidence of heart failure (HF) even after adjustment for well established risk factors for HF such as hypertension and ischaemic heart disease. The resulting specific form of cardiomyopathy is known as diabetic cardiomyopathy” (DCM). Pathogenetic mechanisms underlying DCM are likely to be multifactorial, from altered myocardial metabolism (hyperglycaemia, hyperinsulinaemia, increased circulating fatty acids and trglycerides) to microvascular disease, autonomic neuropathy, and altered myocardial structure with fibrosis. Current medical treatment recommendations from scientific societies on HF in patients with diabetes mellitus (DM) do not differ from those for patients without DM. Regarding the effect of different hypoglycaemic drugs on HF in patients with DM, and considering the best available current evidence, the sodium-glucose-co-transporter 2 inhibitors and metformin seem to be especially advantageous regarding the effects in patients with T2D and HF.


Heart failure Diabetes mellitus Diabetic cardiomyopathy Cardiac lipotoxicity Left ventricular ejection fraction Diastolic dysfunction Systolic dysfunction 



This work wfrom Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain; CIBERDEM, a research network initiative of Instituto de Salud Carlos III, Spain and from la Fundació Marató TV3 (Grant number 201602.30.31) of Spain.


  1. Adameova A, Dhalla NS (2014) Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 19:25CrossRefPubMedGoogle Scholar
  2. Angin Y, Steinbusch LK, Simons PJ, Greulich S, Hoebers NT, Douma K, van Zandvoort MA, Coumans WA, Wijnen W, Diamant M, Ouwens DM, Glatz JF, Luiken JJ (2012) CD36 Inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochem J 448:43CrossRefPubMedGoogle Scholar
  3. Asrih M, Lerch R, Papageorgiou I, Pellieux C, Montessuit C (2012) Differential regulation of stimulated glucose transport by free fatty acids and PPARα or –δ agonists in cardiac myocytes. Am J Physiol Endocrinol Metab 302:E872CrossRefPubMedGoogle Scholar
  4. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998CrossRefPubMedPubMedCentralGoogle Scholar
  5. Bloch A, Crittin J, Barras C, Jeannet M (1980) Hypertrophic cardiomyopathy and HLA. N Engl J Med 302:1033PubMedGoogle Scholar
  6. Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, Targher G (2012) Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35:389CrossRefPubMedPubMedCentralGoogle Scholar
  7. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213CrossRefPubMedGoogle Scholar
  8. Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93:870CrossRefPubMedGoogle Scholar
  9. Caballero L, Kou S, Dulgheru R, Gonjilashvili N, Athanassopoulos GD, Barone D, Baroni M, Cardim N, Gomez de Diego JJ, Oliva MJ, Hagendorff A, Hristova K, Lopez T, Magne J, Martinez C, de la Morena G, Popescu BA, Penicka M, Ozyigit T, Rodrigo Carbonero JD, Salustri A, Van De Veire N, Von Bardeleben RS, Vinereanu D, Voigt JU, Zamorano JL, Bernard A, Donal E, Lang RM, Badano LP, Lancellotti P (2015) Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging 16:1031PubMedGoogle Scholar
  10. Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 162:938CrossRefPubMedGoogle Scholar
  11. Cesario DA, Brar R, Shivkumar K (2006) Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin N Am 35:601CrossRefGoogle Scholar
  12. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667CrossRefPubMedGoogle Scholar
  13. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 314:1547–1552CrossRefPubMedGoogle Scholar
  14. Debono M, Cachia E (2007) The impact of Cardiovascular Autonomic Neuropathy in diabetes: is it associated with left ventricular dysfunction? Auton Neurosci 132:1CrossRefPubMedGoogle Scholar
  15. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV (2000) Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101:2271CrossRefPubMedGoogle Scholar
  16. Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, Turco S, Capaldo B, Sibilio G (2005) Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 22:1720CrossRefPubMedGoogle Scholar
  17. Diamant M, Lamb HJ, Smit JW, de Roos A, Heine RJ (2005) Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation. Diabetologia 48:1669CrossRefPubMedGoogle Scholar
  18. Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533CrossRefGoogle Scholar
  19. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive Investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366:1279CrossRefGoogle Scholar
  20. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049CrossRefPubMedPubMedCentralGoogle Scholar
  21. Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, Pignonblanc PG, Croisille P, Ovize M, Groisne L, Moulin P, Gillebert TC, Derumeaux G (2011) Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 24:1268CrossRefPubMedGoogle Scholar
  22. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA (2013) Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6:395CrossRefPubMedGoogle Scholar
  23. Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH (2005) Screening for heart disease in diabetic subjects. Am Heart J 149:349CrossRefPubMedGoogle Scholar
  24. Fitchett DH, Udell JA, Inzucchi SE (2017) Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19:43CrossRefPubMedGoogle Scholar
  25. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, Investigators SENIORS (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215CrossRefPubMedGoogle Scholar
  26. Frangogiannis NG (2014) The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 11:255CrossRefPubMedPubMedCentralGoogle Scholar
  27. From AM, Scott CG, Chen HH (2009) Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol 103:1463CrossRefPubMedPubMedCentralGoogle Scholar
  28. Goldberg IJ, Trent CM, Schulze PC (2012) Lipid metabolism and toxicity in the heart. Cell Metab 15:805CrossRefPubMedPubMedCentralGoogle Scholar
  29. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, Investigators CHARM (2003) Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772CrossRefPubMedGoogle Scholar
  30. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group (2015) Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232CrossRefPubMedGoogle Scholar
  31. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Køber L, Torp-Pedersen C (2004) Danish Investigatord of Arrhythmia and Mortality on Dofetilde Study Group. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43:771CrossRefPubMedGoogle Scholar
  32. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (1998) UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837CrossRefGoogle Scholar
  33. Inzucchi SE, Masoudi FA, McGuire DK (2007) Metformin therapy in patients with type 2 diabetes complicated by heart failure. Am Heart J 154:e45CrossRefPubMedGoogle Scholar
  34. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668CrossRefPubMedPubMedCentralGoogle Scholar
  35. Jadhav A, Tiwari S, Lee P, Ndisang JF (2013) The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther 345:239CrossRefGoogle Scholar
  36. Jarnert C, Landstedt-Hallin L, Malmberg K, Melcher A, Ohrvik J, Persson H, Rydén L (2009) A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. Eur J Heart Fail 11:39CrossRefPubMedGoogle Scholar
  37. Jensen MT, Sogaard P, Andersen HU, Bech J, Hansen TF, Galatius S, Jørgensen PG, Biering-Sørensen T, Møgelvang R, Rossing P, Jensen JS (2014) Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia 57:672CrossRefPubMedGoogle Scholar
  38. Jørgensen PG, Jensen MT, Mogelvang R, von Scholten BJ, Bech J, Fritz-Hansen T, Galatius S, Biering-Sørensen T, Andersen HU, Vilsbøll T, Rossing P, Jensen JS (2016) Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. Diab Vasc Dis Res 13:321CrossRefPubMedGoogle Scholar
  39. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ (2011) Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 306:856CrossRefPubMedPubMedCentralGoogle Scholar
  40. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study JAMA 241:2035PubMedGoogle Scholar
  41. Kawata T, Daimon M, Miyazaki S, Ichikawa R, Maruyama M, Chiang SJ, Ito C, Sato F, Watada H, Daida H (2015) Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 14:98CrossRefPubMedPubMedCentralGoogle Scholar
  42. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374:1321CrossRefPubMedGoogle Scholar
  43. Khatter JC, Sadri P, Zhang M, Hoeschen RJ (1996) Myocardial angiotensin II (Ang II) receptors in diabetic rats. Ann N Y Acad Sci 793:466CrossRefPubMedGoogle Scholar
  44. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22:1543CrossRefPubMedGoogle Scholar
  45. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR (2007) CD36 Expression contributes to age-induced cardiomyopathy in mice. Circulation 116:2139CrossRefPubMedGoogle Scholar
  46. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD (2014) Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384:2235CrossRefPubMedGoogle Scholar
  47. Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Med 130:S40CrossRefGoogle Scholar
  48. Levelt E, Pavlides M, Banerjee R, Mahmod M, Kelly C, Sellwood J, Ariga R, Thomas S, Francis J, Rodgers C, Clarke W, Sabharwal N, Antoniades C, Schneider J, Robson M, Clarke K, Karamitsos T, Rider O, Neubauer S (2016) Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol 68:53CrossRefPubMedPubMedCentralGoogle Scholar
  49. Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO, Wong E, Sohani ZN, Bala MM, Rios LP, Malaga G, Ebrahim S, Shen J, Zhang L, Zhao P, Chen Q, Wang Y, Guyatt GH, Sun X (2016) Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord 16:91CrossRefPubMedPubMedCentralGoogle Scholar
  50. Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjörnsdottir S (2012) The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia 55:2946CrossRefGoogle Scholar
  51. Liu JE, Robbins DC, Palmieri V, Bella JN, Roman MJ, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB (2003) Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J Am Coll Cardiol 41:2022CrossRefPubMedGoogle Scholar
  52. Lopaschuk GD, Tahiliani AG, Vadlamudi RV, Katz S, McNeill JH (1983) Cardiac sarcoplasmic reticulum function in insulin- or carnitine-treated diabetic rats. Am J Phys 245:H969–H976Google Scholar
  53. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U (2009) Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 30:850CrossRefPubMedPubMedCentralGoogle Scholar
  54. Masoudi FA, Inzucchi SE (2007) Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99:113BCrossRefPubMedGoogle Scholar
  55. McAlister FA, Eurich DT, Majumdar SR, Johnson JA (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10:703CrossRefPubMedGoogle Scholar
  56. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, Held P, Michelson E, Olofsson B (2003) CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 5:261CrossRefPubMedGoogle Scholar
  57. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993CrossRefPubMedGoogle Scholar
  58. Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137CrossRefPubMedPubMedCentralGoogle Scholar
  59. Mythri S, Rajeev H (2015) Left Ventricular Diastolic Dysfunction (LVDD) & Cardiovascular Autonomic Neuropathy (CAN) in Type 2 Diabetes Mellitus (DM): A Cross-Sectional Clinical Study. J Clin Diagn Res 9:OC18Google Scholar
  60. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative (2017 Jun 12) Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med.
  61. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2003) American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108:2941CrossRefGoogle Scholar
  62. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S, Siebelink HM, Smit JW, Diamant M, Romijn JA, de Roos A, Leung DY, Lamb HJ, Bax JJ (2010) Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 122:2538CrossRefGoogle Scholar
  63. Orea-Tejeda A, Colín-Ramírez E, Castillo-Martínez L, Asensio-Lafuente E, Corzo-León D, González-Toledo R, Rebollar-González V, Narváez-David R, Dorantes-García J (2007) Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Investig Clin 59:103Google Scholar
  64. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319CrossRefGoogle Scholar
  65. Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP, Zuithoff NP, Rutten FH, Hoes AW (2011) Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 13:518CrossRefPubMedGoogle Scholar
  66. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DL DM, Carvedilol Prospective Randomized Cumulative Survival Study Group (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651CrossRefPubMedGoogle Scholar
  67. Park TS, Goldberg IJ (2012) Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin 8:633CrossRefPubMedPubMedCentralGoogle Scholar
  68. Pepino MY, Kuda O, Samovski D, Abumrad NA (2014) Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr 34:281CrossRefPubMedPubMedCentralGoogle Scholar
  69. Pérez A, Wägner AM, Carreras G, Giménez G, Sánchez-Quesada JL, Rigla M, Gómez-Gerique JA, Pou JM, de Leiva A (2000) Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. Arch Intern Med 160:2756CrossRefPubMedGoogle Scholar
  70. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709CrossRefPubMedGoogle Scholar
  71. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309CrossRefPubMedGoogle Scholar
  72. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG (2001) Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24:5CrossRefPubMedGoogle Scholar
  73. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891CrossRefPubMedGoogle Scholar
  74. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B (1977) Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60:884CrossRefPubMedGoogle Scholar
  75. Revuelta-López E, Cal R, Julve J, Rull A, Martínez-Bujidos M, Perez-Cuellar M, Ordoñez-Llanos J, Badimon L, Sanchez-Quesada JL, Llorente-Cortés V (2015) Hypoxia worsens the impact of intracellular triglyceride accumulation promoted by electronegative low-density lipoprotein in cardiomyocytes by impairing perilipin 5 upregulation. Int J Biochem Cell Biol 65:257CrossRefPubMedGoogle Scholar
  76. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54:1524CrossRefGoogle Scholar
  77. Rosengren A, Vestberg D, Svensson AM, Kosiborod M, Clements M, Rawshani A, Pivodic A, Gudbjörnsdottir S, Lind M (2015) Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol 3:876CrossRefPubMedGoogle Scholar
  78. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595CrossRefPubMedGoogle Scholar
  79. Sánchez-Quesada JL, Vinagre I, De Juan-Franco E, Sánchez-Hernández J, Bonet-Marques R, Blanco-Vaca F, Ordóñez-Llanos J, Pérez A (2013) Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol 12:112CrossRefPubMedPubMedCentralGoogle Scholar
  80. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317CrossRefPubMedGoogle Scholar
  81. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5:333CrossRefPubMedPubMedCentralGoogle Scholar
  82. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529CrossRefPubMedGoogle Scholar
  83. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM (2003 May 7) Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 41(9):1510–1518CrossRefPubMedGoogle Scholar
  84. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47:332CrossRefPubMedGoogle Scholar
  85. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685CrossRefGoogle Scholar
  86. Standl E, Schnell O, McGuire DK (2016) Heart failure considerations of Antihyperglycemic medications for type 2 diabetes. Circ Res 118:1830CrossRefPubMedGoogle Scholar
  87. Steinbusch LK, Schwenk RW, Ouwens DM, Diamant M, Glatz JF, Luiken JJ (2011) Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell Mol Life Sci 68:2525CrossRefPubMedPubMedCentralGoogle Scholar
  88. Swedberg K, Komajda M, Bӧhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885CrossRefPubMedGoogle Scholar
  89. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731CrossRefPubMedPubMedCentralGoogle Scholar
  90. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P (2003) DIABHYCAR Study Group (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 26:855CrossRefPubMedGoogle Scholar
  91. Velez M, Kohli S, Sabbah HN (2014) Animal models of insulin resistance and heart failure. Heart Fail Rev 19:1CrossRefPubMedGoogle Scholar
  92. Vinagre I, Sánchez-Quesada JL, Sánchez-Hernández J, Santos D, Ordoñez-Llanos J, De Leiva A, Pérez A (2014) Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc Diabetol 13:34CrossRefPubMedPubMedCentralGoogle Scholar
  93. von Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Rydén L (2004) Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 90:1483CrossRefGoogle Scholar
  94. von Scholten BJ, Hasbak P, Christensen TE, Ghotbi AA, Kjaer A, Rossing P, Hansen TW (2016) Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia 59:371CrossRefGoogle Scholar
  95. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS (2003) Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108:977CrossRefPubMedGoogle Scholar
  96. Westermann D, Rutschow S, Jäger S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschöpe C (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56:641CrossRefPubMedGoogle Scholar
  97. WRITING COMMITTEE MEMBERS, ACC/AHA TASK FORCE MEMBERS (2016) 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 22:659CrossRefGoogle Scholar
  98. Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M (2007) Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 153:1055CrossRefPubMedGoogle Scholar
  99. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:2067CrossRefPubMedGoogle Scholar
  100. Zhao XY, Hu SJ, Li J, Mou Y, Chen BP, Xia Q (2006) Decreased cardiac sarcoplasmic reticulum Ca2+ −ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats. J Physiol Biochem 62:1CrossRefPubMedGoogle Scholar
  101. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Núria Alonso
    • 1
    • 2
    • 3
    • 5
    Email author
  • Pedro Moliner
    • 4
    • 5
  • Dídac Mauricio
    • 1
    • 2
    • 3
    • 5
  1. 1.Department of Endocrinology and Nutrition ServiceUniversity Hospital Germans Trias i PujolBadalonaSpain
  2. 2.Centro de Investigación Biomédica Sobre Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIIIMadridSpain
  3. 3.Institut de Recerca Biomèdica de LleidaLleidaSpain
  4. 4.BadalonaSpain
  5. 5.Department of MedicineBarcelona Autonomous University (UAB)BarcelonaSpain

Personalised recommendations